Testing the construct validity of the three DSM-IV cluster groupings of personality disorders, in terms of neuropsychological, psychophysiological, and personality traits measures, was the purpose of this study. The results hardly confirm significant differences between B and C cluster groups in their neuropsychological functioning, but, instead, suggest that Cluster A could have some empirical validity based on executive prefrontal deficits (concept formation and sustained attention tasks) and clinical features. Similarly, no consistent differences among groups emerge when psychophysiological measures are compared. With regard to the Big-Five personality dimensions, the results also indicate that clusters may be more heterogeneous than the DSM-IV suggests. It appears, therefore, that the categorical division of DSM personality disorders into three discrete clusters may not be empirically justified.

Therapeutics used for the treatment of cancer can generate cognitive deterioration. Any advance in the prevention of neurotoxicity would be of major importance. Omega 3, a group of polyunsaturated fatty acids, may play a prominent role in this regard. Omega 3 fatty acids exert their protective effects through multiple direct and indirect pathophysiological mechanisms. Evidence has been obtained about their use in this setting both from preclinical and clinical trials, as well as from studies on their use in other pathologies as prevalent as Alzheimer's disease and other type of dementias. This is why studies are required to confirm the hypothesis that omega 3 supplements may prevent cancer treatment-induced brain damage.

51-58Resumen Los tratamientos usados para el cáncer pueden generar deterioro cognitivo, así que cualquier avance en la prevención de esta toxicidad es de gran importancia. Los ácidos grasos poliinsaturados (AGPI) omega 3 pueden jugar un papel destacado en este aspecto. Realizan su labor protectora a través de multitud de mecanismos fisiopatológicos directos e indirectos. Se han extraído evidencias para su uso en este aspecto tanto de estudios preclínicos y clínicos como de estudios sobre su uso en otras enfermedades tan prevalentes como la enfermedad de Alzheimer (EA) y otro tipo de demencias. Por ello es preciso realizar estudios que confirmen la hipótesis de que los suplementos de omega 3 pueden prevenir el daño cerebral inducido por los tratamientos oncológicos. (creativecommons.org/licenses/by-nc-nd/4.0/). ARTÍCULO DE REVISIÓN¿Pueden los suplementos de omega 3 prevenir la toxicidad neurocognitiva de los tratamientos oncológicos?